Tumor-infiltrating lymphocytes affect the efficacy of trastuzumab-based treatment in human epidermal growth factor receptor 2-positive breast cancer
- 417 Downloads
Immune responses play an important role in interrupting the progression of cancer cells. Tumor-infiltrating lymphocytes (TILs) are basic components of the immune system. In triple negative breast cancer, increased number of TILs is associated with excellent prognosis and response of chemotherapy. Here, we investigated whether TILs affect the efficacy of trastuzumab-based treatment in human epidermal growth factor receptor 2 (HER2)-positive breast cancer.
The study included 97 patients with stage I-III HER2-positive breast cancer. All patients were preoperatively treated with an anthracycline-based combination regimen, followed by taxane with trastuzumab from 2009 to 2013. Pathological complete response (pCR) was defined as the disappearance of invasive cancer cells regardless of the presence of in situ components. TILs were evaluated using pre-therapeutic needle biopsy specimens. We assessed the percentage of the breast stroma with TILs over the total intratumoral stroma and classified the specimens in three grades: TILs1+ < 30%, TILs2+ 30–50%, and TILs3+ > 50%.
Overall, 80.4% of the specimens were TILs1+, 15.5% were TILs2+ and 4.1% were TILs3+. The pCR rate was 44.9% (35/78) in the TILs1+ cases, 80.0% (12/15) in the TILs2+ cases and 75.0% (3/4) in the TILs3+ cases. TILs were significantly associated with pCR (P = 0.0228). Multivariate analysis using TILs, hormone receptor (HR), nuclear grade (NG) and age indicated that TILs (OR 4.32, 95% CI 1.04–23.33, P = 0.0436) and HR (OR 8.76, 95% CI 3.30–25.44, P < 0.0001) were independent predictors for pCR.
TILs are associated with the efficacy of trastuzumab-based treatment in HER2-positive breast cancer.
KeywordsTumor-infiltrating lymphocytes Human epidermal growth factor receptor 2 Breast cancer Neoadjuvant chemotherapy Pathology
Compliance with ethical standards
Conflict of interest
Yoshinori Ito received manuscript fees from Eisai, Novartis and Taiho. He also received research grants from MSD, Astra Zeneca, Novartis, Parexel, Chugai and Lilly. Shinji Ohno received honoraria from Astra Zeneca, Eisai, Chugai, Taiho, Pfizer, Novartis and Kyowa-kirin. The other authors declare that they have no conflict of interest.
- 2.Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005;23:3676–85.CrossRefPubMedGoogle Scholar
- 4.Buzdar AU, Valero V, Ibrahim NK, Francis D, Broglio KR, Theriault RL, et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res. 2007;13:228–33.CrossRefPubMedGoogle Scholar
- 7.Denkert C, von Minckwitz G, Brase JC, Sinn BV, Gade S, Kronenwett R, et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without Carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol. 2015;33:983–91.CrossRefPubMedGoogle Scholar
- 8.Issa-Nummer Y, Darb-Esfahani S, Loibl S, Kunz G, Nekljudova V, Schrader I, et al. Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer—a substudy of the neoadjuvant GeparQuinto trial. PLoS One. 2013;8:e79775. https://doi.org/10.1371/journal.pone.0079775.CrossRefPubMedPubMedCentralGoogle Scholar
- 10.Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014;32:2959–66.CrossRefPubMedPubMedCentralGoogle Scholar
- 11.International Union Against Cancer (UICC). TNM classification of malignant tumors. 7th ed. New York: Wiley; 2009.Google Scholar
- 12.The Japanese Breast Cancer Society. General rules for clinical and pathological recording of breast cancer. 17th ed. Tokyo: Kanehara & Co, Ltd; 2012.Google Scholar
- 19.Denkert C, Huober J, Loibl S, Prinzler J, Kronenwett R, Esfahani SD, et al. HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer. Breast Cancer Res. 2013;15:R11. https://doi.org/10.1186/bcr3384.CrossRefPubMedPubMedCentralGoogle Scholar
- 20.Salgado R, Denkert C, Camphell C, Saras P, Nucifero P, Aura C, et al. Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab-a secondary analysis of the NeoALTTO trial. JAMA Oncol. 2015;1:448–54. https://doi.org/10.1001/jamaoncol.2015.0830.CrossRefPubMedPubMedCentralGoogle Scholar
- 21.Swisher SK, Wu Y, Castaneda CA, Lyons GR, Yang F, Tapia C, et al. Interobserver agreement between pathologists assessing tumor-infiltration lymphocytes (TILs) in breast cancer using methodology proposed by the international TILs working group. Ann Surg Oncol. 2016;23:2242–8.CrossRefPubMedGoogle Scholar